Abstract
Hypophosphatasia (HPP) is a rare, inherited metabolic disorder caused by deficient tissue-nonspecific alkaline phosphatase activity. This study assessed the impact of treatment with asfotase alfa on patient-reported outcomes (PROs) in adults with pediatric-onset HPP. A longitudinal, telephone-based survey was administered to eligible individuals enrolled in a patient support program. Interviews were conducted at study entry (prior to asfotase alfa initiation) and after 3, 6, and 12 mo. PROs—Patient Health Questionnaire-9 [PHQ-9], Work Productivity and Activity Impairment Questionnaire: Specific Health Problem [WPAI:SHP], Patient-Reported Outcomes Measurement Information System 29 [PROMIS-29], and Routine Assessment of Patient Index Data 3 [RAPID3]—were assessed at each time point. Appropriate statistical tests were performed to assess score changes. Among 50 enrolled patients (mean age: 46 yr [SD: 15.4]; 80% female; 94% White), 49 were evaluable at 3 mo, 44 at 6 mo, and 29 at 12 mo. By month 3, statistically significant improvements from baseline were detected in PHQ-9 scores (10.6 vs 5.8 [P < .0001]), PROMIS-29 domain scores (overall physical function: 38.0 vs 43.0 [P = .001]; anxiety: 57.5 vs 51.5 [P = .0011]; fatigue: 63.3 vs 55.3 [P < .0001]; sleep disturbances: 58.8 vs 54.3 [P = .0099]; ability to participate in social roles and activities: 42.6 vs 47.7 [P = .0012]; and pain interference: 63.8 vs 58.4 [P = .001]), and RAPID3 domain scores (functional status: 2.7 vs 1.1 [P < .0001]; pain tolerance: 6.0 vs 3.2 [P < .0001]; and global health estimate: 5.1 vs 2.7 [P < .0001]). Improvements persisted at month 12. Patients also showed improvements in WPAI:SHP domain scores at month 6 (presenteeism: 39.6% vs 14.1% [P < .0001] and work productivity loss: 41.9% vs 14.1% [P < .0001]). Treatment with asfotase alfa was associated with improved quality of life across several domains. Hypophosphatasia (HPP) is a rare, inherited disorder that may cause a variety of symptoms. Asfotase alfa is currently the only treatment approved for patients with HPP. This study measured the impact of asfotase alfa on the quality of life, mental health, productivity at work, and disease impact in adults with pediatric-onset HPP who were participating in a patient support program. Patients were interviewed before they began treatment and after 3, 6, and 12 mo of treatment. Among 50 patients who started the study (average age 46 yr; 80% female; 94% White), 49 were interviewed at 3 mo, 44 at 6 mo, and 29 at 12 mo. Patients reported improvements in their physical functioning, anxiety, fatigue, sleep problems, interference of pain with daily life, and ability to participate in their social roles and daily activities. They also showed decreases in their symptoms of depression and increases in work productivity. Patients showed improvements in their ability to function, tolerance of pain, and general feelings about their health. Most gains in quality of life were noticeable after 3 mo of treatment and continued after 12 mo. Asfotase alfa was effective at improving quality of life for adult patients with pediatric-onset HPP.
Funding Information
  • Alexion

This publication has 25 references indexed in Scilit: